SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending following reports that the company is preparing an offer to acquire eBay, fueling investor speculation about a potential strategic pivot into a larger e-commerce marketplace. While the community is debating the feasibility and financing of such a large-scale acquisition, many are focused on the potential for a short squeeze and the stock's significant move on high volume.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is experiencing intense momentum as traders speculate on a potential short squeeze, driven by a high short interest, significant cost-to-borrow fees, and a scarcity of available shares. The community is actively discussing the stock's potential to rally further ahead of upcoming earnings, with many users advocating for a 'diamond hands' strategy to pressure short sellers into covering their positions.

AIOS Tech, Inc. is an investment holding company, which engages in the provision of financing solutions to small- and mid-size enterprises. The company was founded on May 29, 2012 and is headquartered in Shanghai, China.

AIOS Tech Inc. - Ordinary Shares - Class A

AIOS Tech Inc.

AIOS Tech Inc. is generating significant buzz due to its low-float profile and extreme price volatility, which has led to intense speculation about potential short squeezes. Community discussions are heavily focused on the stock's recent performance following a reverse split, with traders debating whether the movement is a genuine breakout or a classic pump-and-dump setup.

Twilio, Inc. engages in the development of communications software, cloud-based platforms, and services. It operates through Twilio Communications and Twilio Segments. The Twilio Communications segment includes the platforms Messaging and Voice. The Twilio Segment involves Segment, Engage, Flex, Email, and others. The company was founded by John Wolthuis, Jeffery G. Lawson, and Evan Cooke in March 2008 and is headquartered in San Francisco, CA.

Twilio Inc - Ordinary Shares Class A

Twilio Inc

Twilio shares are rallying following the company's inclusion in the S&P MidCap 400 index, a move that has sparked renewed momentum among investors. Community sentiment is shifting toward optimism, with many highlighting potential AI-driven voice demand and operational discipline as foundational strengths for the stock's future performance.

Lionsgate Studios Corp. operates as a standalone, pure-play content company focused on creating, producing, and distributing premium entertainment across multiple formats and platforms. It operates through the following segments: Motion Picture and Television Production. The Motion Picture segment includes the development and production of feature films, acquisition of North American and worldwide distribution rights, North American theatrical, home entertainment, and television distribution of produced and acquired films, as well as the worldwide licensing of distribution rights. The Television Production segment covers the development, production, and worldwide distribution of television content, including series, television movies, mini-series, and non-fiction programming. The company was founded on January 13, 2025 and is headquartered in Vancouver, Canada.

Lionsgate Studios Corp. - Ordinary Shares - New

Lionsgate Studios Corp.

Lionsgate Studios is trending as the market reacts to strong box office momentum from the Michael Jackson biopic, fueling investor sentiment around the company's standalone studio potential. Community discussions are heavily focused on the stock's role as a high-conviction buyout candidate, with participants tracking significant institutional accumulation and strategic board moves as potential indicators of an upcoming acquisition.

Dogelon Mars

Dogelon Mars is trending amid persistent community speculation regarding potential token burns and future utility, with holders actively debating whether the project's historical ties to Elon Musk and low market cap offer a contrarian opportunity. While sentiment remains highly polarized between long-term supporters hoping for a resurgence and critics labeling the asset a legacy pump-and-dump, the community continues to mobilize around high-visibility social media activity to drive momentum.

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals is trending as investors show strong enthusiasm following the "Best New Drug" award for Revuforj and anticipation for key data presentations at the upcoming ASH meeting. The community is actively discussing a potential buyout by Incyte due to strategic synergies, with many highlighting the stock's significant upside potential relative to its current valuation and high short interest.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Berkeley Heights, NJ.

Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals is trending as investors weigh strong commercial launch momentum for TONMYA against concerns over proposed corporate governance measures, including authorization for future reverse stock splits. The community is actively debating the company's long-term capital strategy versus the potential for clinical success in the fibromyalgia market.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending as investors digest the recent energization of the Sweetwater 1 substation while speculating on future hyperscaler deal flow ahead of upcoming earnings. Community sentiment remains polarized, with many debating the company's execution speed versus the recent decline in share price and ongoing retail frustrations over the timing of corporate communications.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending as investors react to conservative 2026 financial guidance and the anticipated impact of the TDAPA reimbursement transition, sparking heated community debate over the company's valuation versus its long-term growth potential. While some shareholders are expressing frustration over the recent stock performance and leadership communication, others are actively focused on the upcoming Phase 3 trial results for REZZAYO and ongoing legislative efforts to secure long-term reimbursement for DefenCath.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity

MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity PR Newswire CAMBRIDGE...

MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update

MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update PR Newswire CAMBRIDGE, Mass., March 26, 2026 48 mg Phase 1 Data Demonstrate Potential Best-in-Class Profile for DA-1726 with 9.1% Weight Loss...

MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control

MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and...

MetaVia Expands Global Patent Protection for Vanoglipel, Supporting Metabolic and Liver Disease Therapy Through 2035

MetaVia Expands Global Patent Protection for Vanoglipel, Supporting Metabolic and Liver Disease Therapy Through 2035 MetaVia Expands Global Patent Protection for Vanoglipel, Supporting Metabolic and...

MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum

MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences...

MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference

MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference PR...

MetaVia Builds Comprehensive Global Patent Protection for DA-1726, Securing Exclusive Rights to Novel Obesity and Metabolic Therapy Through 2041

MetaVia Builds Comprehensive Global Patent Protection for DA-1726, Securing Exclusive Rights to Novel Obesity and Metabolic Therapy Through 2041 MetaVia Builds Comprehensive Global Patent Protection...

What Does the Market Think About MetaVia Inc?

MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option

MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering...

MetaVia Stock Slides After Pricing Public Offering

(RTTNews) - MetaVia Inc. (MTVA) shares traded at $3.4050, down 39.03% or $2.18 lower, after the company announced the pricing of an $8.1 million underwritten public offering...

MetaVia, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. Its pipeline includes ANA001, a proprietary oral niclosamide formulation, Gemcabene, which is assessed as an acute indication for COVID-19, NB-01, a treatment for painful diabetic neuropathy, and NB-02, which has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases. The company was founded on October 30, 2014 and is headquartered in Cambridge, MA.

Current Price	$1.44
Prev Close	$1.44
Open	$1.45
Dividend Yield	0.00%
50-Day Moving Average	$1.46
Beta	0.98
Avg. Volume	143,239.88
PE Ratio	-0.16

52-Week High	$19.03
52-Week Low	$1.17
Market Capitalization	$7.33M
EPS (Annual)	-$7.35
Price to Book	0.62
Revenue Per Employee	$0.00

MTVA
MetaVia Inc.

Feed

News

Sentiment

Fundamentals

Info

Latest MTVA News

MTVAMetaVia Inc.